Kueichen Chiang

Title: Kueichen Chiang: Innovator in Immunosuppressive Antibodies

Introduction

Kueichen Chiang is a prominent inventor based in Tokyo-to, Japan. He has made significant contributions to the field of immunology, particularly through his innovative work on monoclonal antibodies. His research focuses on developing antibodies with immunosuppressive activity, which can have important applications in medical treatments.

Latest Patents

Kueichen Chiang holds a patent for a monoclonal antibody that exhibits excellent immunosuppressive activity. The patent, titled "Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof," describes a monoclonal antibody or an antigen binding fragment that binds to a specific peptide sequence, SSVLYGGPPSAA (SEQ ID NO: 1). This invention is notable for its higher binding affinity for core histone compared to histone H1, which could lead to advancements in therapeutic strategies.

Career Highlights

Chiang is affiliated with Josai University Corporation, where he continues to engage in groundbreaking research. His work has not only contributed to the scientific community but also holds potential for practical applications in medicine. His dedication to innovation in immunology is evident through his focused research efforts.

Collaborations

Kueichen Chiang collaborates with esteemed colleagues, including Shuji Sato and Takeshi Goto. These partnerships enhance the research environment and foster the exchange of ideas, leading to further advancements in their respective fields.

Conclusion

Kueichen Chiang's contributions to the field of immunology through his patent on monoclonal antibodies highlight his role as an innovator. His work at Josai University Corporation and collaborations with fellow researchers underscore the importance of teamwork in scientific discovery. The advancements he is making in immunosuppressive therapies could have a lasting impact on medical treatments.